BRCA1 and BRCA2 mutation carriers as potential candidates for chemoprevention trials

Ephrat Levy-Lahad*, Michal Krieger, Orit Gottfeld, Paul Renbaum, Gaya Klein, Shlomit Eisenberg, Amnon Lahad, Bella Kaufman, Raphael Catane

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


The identification of cancer susceptibility genes offers new avenues for selecting high-risk individuals as subjects for chemoprevention trials. Because carriers of predisposing mutations are at high risk, they are more likely to enroll and comply with chemoprevention trials, and meaningful results can be achieved with smaller numbers of participants and shorter periods of follow-up. Such studies have immediate benefits for carriers themselves, but they are also likely to result in effective chemopreventive strategies for the general population. In this review, we discuss BRCA1 and BRCA2 carriers as potential candidates for breast and ovarian cancer chemoprevention trials. The existence of a large population with a high frequency of easily identifiable BRCA1/2 mutations can provide ample opportunity for such studies. However, the possibility that tumor characteristics and hormonal profile of BRCA1/BRCA2 related cancers are not completely equivalent to cancers in the general population should be borne in mind. (C) 2000 Wiley-Liss, Inc.

Original languageAmerican English
Pages (from-to)13-18
Number of pages6
JournalJournal of Cellular Biochemistry
Issue numberSUPPL. 34
StatePublished - 2000


  • Ashkenazi Jews
  • Breast cancer
  • Cancer genetics
  • Israel
  • Ovarian cancer


Dive into the research topics of 'BRCA1 and BRCA2 mutation carriers as potential candidates for chemoprevention trials'. Together they form a unique fingerprint.

Cite this